Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua T. Brumm
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Beta
- 1.26
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 10.86
Financials
Revenue
$0.00-100.0%Net Income
$-22.69MEBITDA
$-24.77MFree Cash Flow
$-19.48MEPS (diluted)
$-0.74Shares Outstanding (diluted)
30.53M+13146.5%Operating Expenses
$28.13MCash & Debt
$171.59MRevenue by Segment (annual)
$10.84MDividend per Share
$24.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.84M | $-153.94M | $-14.78 |
| 2024 | $0.00 | $-48.52M | $-63.22 |
| 2023 | $10.0K | $-36.90M | $-58.25 |
| 2022 | $75.0K | $-46.69M | $-88.88 |
| 2021 | $1.16M | $-63.43M | $-123.27 |
| 2020 | $10.16M | $-51.03M | $-111.60 |
| 2019 | $0.00 | $-54.12M | $-133.84 |
| 2018 | $0.00 | $-48.27M | $-117.61 |
| 2017 | $0.00 | $-33.28M | $-113.22 |
| 2016 | $18.5K | $-31.81M | $-149.65 |
| 2015 | $20.07M | $-12.77M | $-67.17 |
| 2014 | $15.03M | $-11.12M | $-60.27 |
| 2013 | $3.99M | $-10.61M | $-199.32 |
| 2012 | $15.26M | $3.66M | $305.64 |
Valuation
CBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·12d ago·Neutral
…ent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 81,525 shares of the Company's ordinary shares to six non-executi…
View source ↗ - Newsglobenewswire.com·23d ago·Neutral
…nt Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company's ordinary shares to two non-executi…
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
…nt Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 58,650 shares of the Company's ordinary shares to two non-executi…
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…harma to Present at September Investor Conferences WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m.
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.67 per share
Typical surprise -0.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.74 vs $-0.74miss
- Wed, Apr 29$-0.70 vs $-0.85beat
- Thu, Feb 26$-4.01 vs $-2.22miss
- Thu, Nov 6$-1.27 vs $-1.01miss
- Wed, Aug 6$-4.93 vs $-2.69miss
- Wed, May 14$-0.04 vs $-5.00beat
Estimates and results for CBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CBIO officers and directors.
- Bought
- $30.8m
- Sold
- $2.0m
9 trades
25 trades
- Brumm Joshua Tsold
- Mcneill Jonathansold
- Lynch Ryansold
- Pinkas Jansold
- Im Ellie Eunkyungsold
- Scalzo Richard Williamsold
- Bispham Barbara Harlinsold
- Brumm Joshua Tsold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CBIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.